Attovia's Dual-Target Platform and Clinical Progress

Attovia Therapeutics, spun out from Alamar Biosciences in 2023, is pursuing a Nasdaq listing to accelerate the development of its lead pipeline candidate, 'ATTO-1310,' based on its ATTOBODY platform. 'ATTO-1310' is a biparatopic biologic targeting interleukin-31 (IL-31), a cytokine known to induce pruritus. It is currently in a Phase 1 clinical trial for patients with chronic pruritus and high-itch atopic dermatitis. The company has already secured $256 million in private funding and plans to enter Phase 2 clinical trials in the first half of 2027. This molecule is expected to overcome the limitations of existing single-target antibodies and demonstrate improved efficacy and durability, making it a potentially innovative treatment in the immunology market.

Braveheart's Introduction of a Cardiac Disease Treatment and Global Clinical Plan

Braveheart Bio, a developer of treatments for hypertrophic cardiomyopathy (HCM), has also joined the Nasdaq IPO pipeline. Braveheart's key asset, 'BHB-1893,' is an oral small-molecule cardiac myosin inhibitor. It was licensed-in from Jiangsu Hengrui Pharmaceuticals in September 2025 for a total of $1.088 billion. This molecule will compete with Bristol Myers Squibb's (BMS) 'Camzyos' and Cytokinetics' 'Myqorzo,' and it has the potential to be a best-in-class drug in terms of ease of administration and pharmacokinetic profile. Hengrui, Braveheart's development partner, has completed a Phase 2 trial in China and is currently conducting a Phase 3 trial in patients with obstructive hypertrophic cardiomyopathy (oHCM). Braveheart plans to initiate a global Phase 3 trial for obstructive HCM in late 2026 and a Phase 3 trial for non-obstructive HCM in the first half of 2027.

Diversification Strategy with a Multi-Target Pipeline

In addition to its lead pipeline candidate, Attovia is building a diversified pipeline to strengthen its competitiveness in the immunology market. 'ATTO-2306,' which simultaneously targets interleukin-31 (IL-31) and interleukin-13 (IL-13) to differentiate the treatment of atopic dermatitis, and 'ATTO-1091,' a triple antagonist targeting TL1A, interleukin-23 (IL-23), and integrin a3B7 for the treatment of inflammatory bowel disease (IBD), are representative examples. Both of these molecules are expected to enter Phase 1 clinical trials in 2027, effectively diversifying the risk associated with a single pipeline. The multi-target technology, which simultaneously inhibits multiple immune pathways, can provide a new alternative for patients with refractory diseases who do not respond to single inhibitors and has the potential to change the treatment paradigm.

Activation of the Biotech IPO Market and Improvement of Funding Environment

Attovia and Braveheart's Nasdaq IPO filings reflect the recovery momentum of the biotech initial public offering (IPO) market in 2026. So far this year, 13 biotech companies have successfully gone public, and the median amount of capital raised has exceeded $300 million, indicating a significant improvement in market liquidity. In July alone, promising companies such as Scribe Therapeutics and Apnimed filed IPO documents, demonstrating an accelerating trend in IPOs. This favorable capital market provides a solid financial foundation for clinical-stage biotech companies to sustain their own clinical development without relying solely on early technology licensing to large multinational pharmaceutical companies, which is significant.